← Eichor
Study identifier: NCT06552429 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Condition: Essential Thrombocythemia  ·  Sponsor: Xiamen Amoytop Biotech Co., Ltd.

PhasePhase 2
Planned participants27
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multicenter, randomized, open-label Phase 2 clinical study. It is aimed to enroll 27 essential thrombocytopenia (ET) patients who are resistant to or intolerant of hydroxyurea(HU). Eligible patients will be randomized to receive either Peginterferon α-2b 135 mcg or Peginterferon α-2b 180 mcg at a ratio of 1:2, and all subjects will go through a target treatment period (Weeks 1 \~ Week 48), an extension treatment period (Weeks 49 \~ Week 96) and a follow-up period (Weeks 97 \~ Week 100). Pharmacokinetics, safety, efficacy will be evaluated.

This description comes directly from the study's public registry record.

Talk to the study team

Lei Zhang  ·  13502118379  ·  zhanglei1@ihcams.ac.cn

Rongfeng Fu  ·  13502118379  ·  furongfeng@ihcams.ac.cn

Always discuss trial participation with your own doctor first.

Locations (8)

Peking Union Hospital, Chinese Academy of Medical SciencesBeijing, ChinaRecruiting
Peking University People's HospitalBeijing, ChinaRecruiting
Union Hospital affiliated to Fujian Medical UniversityFujian, ChinaRecruiting
Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaRecruiting
Harbin First HospitalHarbin, ChinaRecruiting
Henan Cancer HospitalHenan, ChinaRecruiting
Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaRecruiting
The First Affiliated Hospital of Zhejiang University School of MedicineZhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06552429